Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label intensified retreatment with ABT-450/r + ABT-267 + peginterferon alfa-2a + ribavirin after prior AbbVie/Abbott DAA virologic failure in chronic hepatitis C
NL-OMON39209Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paritaprevir, ritonavir, glecaprevir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (3 arms), sponsored by AbbVie Inc. Primary endpoints: SVR12actual and Safety and tolerability. Started Jul 2014; status: active, not recruiting.
02
Drugs
paritaprevirritonavirglecaprevirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON39209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39209.